Skip to Main Content
For healthcare professionals

DAREON®‑9: Phase Ib study of obrixtamig plus chemotherapy in relapsed/refractory SCLC (NCT05990738)

 

DAREON®-9: A Phase Ib open-label dose escalation and dose confirmation safety study of intravenous DLL3/CD3 T-cell engager (obrixtamig) in combination with a single agent chemotherapy for the treatment of patients with relapsed/refractory SCLC after platinum-based chemotherapy (NCT05990738)1

DLL3/CD3 T-cell engager DAREON®-9, NCT05990738
DLL3/CD3 T-cell engager DAREON®-9, NCT05990738

AE, adverse event; CD3, cluster of differentiation 3; DLL3, delta-like canonical Notch ligand 3; DLT, dose-limiting toxicity; DoR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; ES-SCLC, extensive-stage small cell lung cancer; MTD, maximum tolerated dose; OR, objective response; PD-1, programmed cell death protein-1; PD-L1; programmed death ligand-1; RDE, recommend dose for expansion; RP2D, recommended Phase II dose; SCLC, small cell lung cancer; SoC, standard of care.

References

  1. ClinicalTrials.gov. NCT05990738. https://clinicaltrials.gov/ct2/show/NCT05990738 (Accessed: February 2026).